Table 1.
JAK inhibitors with documented efficacy for treating AA.
| IC50 (nM) | ||||
|---|---|---|---|---|
| JAK1 | JAK2 | JAK3 | TYK2 | |
| Tofacitinib (53) | 15 | 71 | 45 | 472 |
| Ruxolitinib (54) | 3.3 | 2.8 | 428 | 19 |
| Baricitinib (53) | 0.78 | 2 | 253 | 14 |
| Abrocitinib (55) | 29 | 803 | >10000 | 1253 |
| Delgocitinib (56) | 2.6 | 2.8 | 13 | 58 |
| Upadacitinib (53) | 0.76 | 19 | 224 | 118 |
| Brepocitinib (57) | 23 | 17 | 77 | 6494 |
| Ritlecitinib (58) | >10000 | >10000 | 33.1 | >10000 |
IC50 values denote the concentration of drug that reduces enzymatic activity of each JAK member by 50%. All reported assays performed in the presence of 1 mM ATP.